Clinical expansion Leverage Rapid Novor’s ongoing clinical studies and EasyM disease response analysis offerings to target biotech and translational medicine groups seeking MS-based protein sequencing to monitor treatment response, especially in multiple myeloma and NDMM cohorts.

Partnerships and channels Capitalize on existing and recent partnerships (Sino Biological, PMCF, Science Exchange) to pursue channel partnerships and co-development deals that broaden service adoption, particularly with manufacturers and CROs needing scalable antibody sequencing services.

HDX-MS AI edge Position the AI-driven HDX-MS epitope mapping service as a differentiator for antibody development programs, targeting R&D teams seeking faster, data-rich epitope insights to accelerate candidate selection and optimization.

Proteomics scale Target mid-market biotechs and contract services with growth in proteomics and antibody sequencing needs, highlighting Rapid Novor’s REmAb sequencing and mass spectrometry capabilities as a cost-effective, scalable alternative to cell-line dependent approaches.

Global reach and funding signals Emphasize the company’s international spin-out pedigree, steady revenue growth, and recent financing as proof points for investors and customers, while pursuing multi-region deals and larger program engagements that align with their $10M–$25M revenue band.</content>